Search

Displaying results 1821 - 1830 of 10000 in total
  1. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Neratinib is currently under investigation for use in many other forms of cancer.

  2. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

    Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE
  3. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.

  4. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

  5. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

    Categories: Drugs Used in Diabetes
  6. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

    Products: Malogen In Oil Liq 100mg/ml
  7. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

  8. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

  9. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis. … [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]

  10. Drug

    Tetradecyl hydrogen sulfate (ester)

    go.drugbank.com/drugs/DB11328
    Approved

    Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids … Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report of injecting a 1% solution into spider angiomas in 144 patients was made.